X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2202) 2202
Publication (199) 199
Conference Proceeding (22) 22
Book / eBook (11) 11
Book Chapter (11) 11
Book Review (8) 8
Dissertation (3) 3
Patent (2) 2
Report (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (838) 838
female (471) 471
index medicus (438) 438
male (431) 431
adult (404) 404
infectious diseases (371) 371
middle aged (368) 368
aged (277) 277
microbiology (234) 234
immunology (194) 194
life sciences (160) 160
antifungal agents - therapeutic use (140) 140
treatment outcome (133) 133
adolescent (130) 130
risk factors (128) 128
medicine, general & internal (121) 121
infections (117) 117
oncology (108) 108
retrospective studies (104) 104
health aspects (102) 102
epidemiology (96) 96
aged, 80 and over (95) 95
therapy (95) 95
young adult (94) 94
child (92) 92
france (91) 91
prospective studies (86) 86
diagnosis (85) 85
care and treatment (81) 81
mortality (77) 77
aids (76) 76
cancer (75) 75
disease (72) 72
infection (71) 71
hiv (69) 69
transplantation (68) 68
pharmacology & pharmacy (67) 67
france - epidemiology (65) 65
patients (65) 65
prognosis (65) 65
child, preschool (64) 64
microbiology and parasitology (64) 64
mycology (63) 63
research (62) 62
aspergillosis (57) 57
antifungal agents (56) 56
hematology (56) 56
chemotherapy (55) 55
analysis (54) 54
animals (54) 54
immunocompromised host (53) 53
mycoses (53) 53
fungal infections (52) 52
abridged index medicus (51) 51
breast cancer (50) 50
fluconazole (50) 50
hiv infections - complications (49) 49
cryptococcosis (48) 48
amphotericin-b (45) 45
mutation (45) 45
risk-factors (45) 45
voriconazole (45) 45
drug therapy (44) 44
infant (43) 43
medicine (43) 43
follow-up studies (42) 42
fungal-infections (42) 42
human health and pathology (42) 42
meningitis (42) 42
tuberculosis (41) 41
human immunodeficiency virus--hiv (39) 39
time factors (39) 39
hiv infections - drug therapy (38) 38
amphotericin b - therapeutic use (37) 37
anti-bacterial agents - therapeutic use (37) 37
clinical trials (37) 37
immunodeficiency (37) 37
infectious disease (37) 37
amphotericin b (36) 36
candida (36) 36
human-immunodeficiency-virus (36) 36
mucormycosis (36) 36
surgery (36) 36
candidemia (35) 35
management (35) 35
survival analysis (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
candidiasis (34) 34
drug therapy, combination (34) 34
mesh: humans (34) 34
risk (34) 34
hiv infection (33) 33
leukemia (33) 33
incidence (32) 32
liposomal amphotericin-b (31) 31
organ transplant recipients (31) 31
research article (31) 31
breast neoplasms - drug therapy (30) 30
breast neoplasms - pathology (30) 30
cohort studies (30) 30
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2016, ISBN 2070179788, 138
Book
2014, ISBN 2070144011, 250
Book
2011, ISBN 2070133257, 153
Book
Mycoses, ISSN 0933-7407, 08/2002, Volume 45, Issue S2, pp. 13 - 13
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10020, pp. 760 - 769
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2012, Volume 54, Issue suppl_1, pp. S23 - S34
Journal Article
1996, Annales de l'Institut culturel autrichien, ISBN 2877111563, Volume 1., 323
Book
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FOLLOW-UP | CHEMOTHERAPY | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 6/2008, Volume 46, Issue 12, pp. 1813 - 1821
Journal Article
Emerging Infectious Diseases, ISSN 1080-6040, 2014, Volume 20, Issue 7, pp. 1149 - 1155
Journal Article
2015, ISBN 2913366813, 270
Book
1970, Théâtre du monde entier, 126
Book
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article